Organogenesis Holdings Inc. (ORGO) News
Filter ORGO News Items
ORGO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ORGO News Highlights
- ORGO's 30 day story count now stands at 3.
- Over the past 1 day, the trend for ORGO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- NOTE and NOV are the most mentioned tickers in articles about ORGO.
Latest ORGO News From Around the Web
Below are the latest news stories about ORGANOGENESIS HOLDINGS INC that investors may wish to consider to help them evaluate ORGO as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Thursday! |
Organogenesis Holdings Inc. (ORGO) Q3 2022 Earnings Call TranscriptGood afternoon, ladies and gentlemen, and welcome to the third quarter 2022 earnings conference call for Organogenesis Holdings Inc. [Operator instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated Including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A risk factors of the company's most recent annual report and its subsequent... |
Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial ResultsCANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results Summary: Net revenue of $116.9 million for the third quarter of 2022, an increase of 3% compared |
Organogenesis Holdings (NASDAQ:ORGO) shareholders have endured a 72% loss from investing in the stock a year agoAs every investor would know, you don't hit a homerun every time you swing. But it would be foolish to simply accept... |
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2022 financial results will be reported after the market closes on Wednesday, November 9th. Management will host a conference call at 5:00 p.m. Eastern Time on Nove |
Will Weakness in Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Stock Prove Temporary Given Strong Fundamentals?With its stock down 36% over the past three months, it is easy to disregard Organogenesis Holdings (NASDAQ:ORGO... |
Top Pharmaceutical Stocks for Q4 2022These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2022. |
10 Best 52-Week Low Small-Cap Stocks to Buy NowIn this article, we discuss the 10 best 52-week low small-cap stocks to buy now. If you want to skip our discussion on the overall economic environment in the US, go to 5 Best 52-Week Low Small-Cap Stocks to Buy Now. The US stock markets have come under pressure as inflation rose faster than expected […] |
Organogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceCANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from Septem |
FDA Clears Organogenesis' Next Generation PuraPly Surgical SolutionOrganogenesis Holdings Inc (NASDAQ: ORGO) has received the FDA 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio. Of the U.S.'s 40 to 50 million surgeries each year, up to 28% of surgical sites must be left open to heal. Related: Organogenesis' Q2 Operating Income Fell 50%, Lowers Annual Guidance. Organogenesis developed PuraPly MZ, a powder designed to support wound healing in deep, tunneling, and complex wounds to support clinicians and patients with these compl |